Nucryo Vascular Competitors and Similar CompaniesClear all

Nucryo Vascular's competitors and similar companies include Venus MedTech, MediRex, ProSomnus Sleep Technologies and Thrombolex.

	Nucryo Vascular NuCryo Vascular is a company that manufactures and distributes the PolarCath balloon dilatation system.	Venus MedTech Venus MedTech (启明医疗) is a company that develops and commercializes transcatheter heart valve medical devices.	MediRex MediRex is an importer, distributor, and marketer of medical devices and technologies.	ProSomnus Sleep Technologies ProSomnus Sleep Technologies is a company that develops and manufactures oral appliance treatment of obstructive sleep apnea and snoring.	Thrombolex Thrombolex is a company engaged in the design, development, manufacture, and distribution of endovascular catheters.
Founding Date	Founding Date 2014	Founding Date 2009	Founding Date 2001	Founding Date 2016	Founding Date 2016
Type	Type Private	Type Public	Type Private	Type Private	Type Private
Tags	Tags Healthcare distribution medical devices medtech	Tags Healthcare distribution medical devices medtech	Tags Healthcare distribution medical devices medtech	Tags Healthcare medical devices medtech therapy	Tags Healthcare distribution medical devices medtech
Locations	Locations San Jose, US HQ	Locations Hangzhou Shi, CN HQ	Locations Bogotá, CO HQ	Locations Pleasanton, US HQ München, DE Oberentfelden, CH	Locations New Britain, US HQ
Employees	Employees 3	Employees 691	Employees 642% increase	Employees 12228% increase	Employees 1910% decrease
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥306.8m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $27.7m (FY, 2023)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods ¥95m (FY, 2025)	Cost of goods N/A	Cost of goods $13.6m (FY, 2023)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit ¥239.5m (FY, 2025)	Gross profit N/A	Gross profit $14m (FY, 2023)	Gross profit N/A
Net income	Net income N/A	Net income (¥407.7m) (FY, 2025)	Net income N/A	Net income ($24.1m) (FY, 2023)	Net income N/A